Correlation Between Ki-67 Proliferation Index and Histopathological Grade in Triple-Negative Breast Cancer: A Study from RSUD Abdul Moeloek, 2024
DOI:
https://doi.org/10.53366/jimki.v12i3.1056Keywords:
TNBC, Ki-67, histopathological grade, proliferation index, breast cancerAbstract
Abstract
Background: Triple-negative breast cancer (TNBC) represents one of the most aggressive breast cancer subtypes and is associated with high recurrence rates and limited targeted treatment options. Ki-67 proliferation index and histopathological grade are commonly used prognostic indicators, yet their relationship within TNBC remains inconsistent across studies. This research aimed to examine the association between Ki-67 expression and tumor grade among TNBC patients at RSUD Abdul Moeloek in 2024. Methods: A retrospective analytical cross-sectional study was conducted using medical records and pathology reports of all TNBC patients diagnosed between January and December 2024. Data were analyzed using Spearman’s rank correlation. Results: Twenty-eight patients met the inclusion criteria. Most participants were within the 40–50-year age group and had grade III tumors. A high Ki-67 index (>20%) was observed in the majority of cases. Spearman’s test revealed no significant correlation between tumor grade and Ki-67 index (r = 0.009; p = 0.964). Conclusion: This study found no meaningful association between Ki-67 expression and histopathological grade in TNBC cases at the study site. Both parameters appear to provide independent prognostic information, underscoring the need for their combined assessment in clinical practice.
References
1. Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, et al. Cancer statistics for the year 2020: An overview. Int J Cancer. 2021;149(4):778–89.
2. Cserni G, Quinn CM, Foschini MP, Bianchi S, Callagy G, Chmielik E, et al. Triple-Negative Breast Cancer Histological Subtypes with a Favourable Prognosis. 2021;1–23.
3. Zhang H, Hicks DG, Turner BM. The Evolution of Ki-67 and Breast Carcinoma : Past Observations , Present Directions , and Future Considerations. 2023.
4. Nielsen TO, Leung SCY, Rimm DL, Dodson A, Acs B, Badve S, et al. Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group. J Natl Cancer Inst. 2021;113(7):808–19.
5. Li L, Han D, Yu Y, Li J, Liu Y. Artificial intelligence-assisted interpretation of Ki-67 expression and repeatability in breast cancer. Diagn Pathol. 2022;17(1):1–10.
6. Zhang A, Wang X, Fan C, Mao X. The Role of Ki67 in Evaluating Neoadjuvant Endocrine Therapy of Hormone Receptor-Positive Breast Cancer. 2021;12(November):1–7.
7. Tyagi A, Salhotra R, Agrawal A, Vashist I, Malhotra RK. Use of Pearson and Spearman correlation testing in Indian anesthesia journals : An audit. 2023.
8. Li F. Prognostic predictive value of Ki-67 in stage I – II triple-negative breast cancer. 2023.
9. Zhang G, Shi Z, Liu L, Yuan H, Pan Z, Li W, et al. The prognostic relevance of p53 and Ki-67 to chemotherapy sensitivity and prognosis in triple-negative breast cancer. 2021;10(2):1082–7.
10. Arafah MA, Ouban A, Ameer OZ, Quek KJ. KI-67 LI Expression in Triple-Negative Breast Cancer Patients and Its Significance. 2021.
11. Abubakr A, Humayun S, Ali T, Khursheed S, Khan A, Khan S, et al. Correlation Between Ki-67 Expression and Tumor Grade in Breast Cancer : A Cross-Sectional Study. 2024;16(12).
12. Sandilya U, Mamatha K. Expression of Ki-67 in Invasive Breast Carcinoma and Its Correlation With Different Clinicopathological Features. 2024;16(9):1–14.
13. Milev H, Desislava Dimitrova, Ivanov I. Assessment of Ki-67 in breast carcinoma: Interobserver variability and comparison between core needle biopsy and resection specimens. Annals of Diagnostic Pathology 80; 2025. p. 152571.
14. Uncu UY, Aksu SA. Correlation of Perfusion Metrics with Ki-67 Proliferation Index and Axillary Involvement as a Prognostic Marker in Breast Carcinoma Cases : A Dynamic Contrast-Enhanced Perfusion MRI Study. 2023.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Jesika Cahya Ningrum
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.